| Literature DB >> 22230803 |
Antoine Claessens1, J Alexandra Rowe.
Abstract
Most human malaria deaths are caused by blood-stage Plasmodium falciparum parasites. Cerebral malaria, the most life-threatening complication of the disease, is characterised by an accumulation of Plasmodium falciparum infected red blood cells (iRBC) at pigmented trophozoite stage in the microvasculature of the brain(2-4). This microvessel obstruction (sequestration) leads to acidosis, hypoxia and harmful inflammatory cytokines (reviewed in (5)). Sequestration is also found in most microvascular tissues of the human body(2, 3). The mechanism by which iRBC attach to the blood vessel walls is still poorly understood. The immortalized Human Brain microvascular Endothelial Cell line (HBEC-5i) has been used as an in vitro model of the blood-brain barrier(6). However, Plasmodium falciparum iRBC attach only poorly to HBEC-5i in vitro, unlike the dense sequestration that occurs in cerebral malaria cases. We therefore developed a panning assay to select (enrich) various P. falciparum strains for adhesion to HBEC-5i in order to obtain populations of high-binding parasites, more representative of what occurs in vivo. A sample of a parasite culture (mixture of iRBC and uninfected RBC) at the pigmented trophozoite stage is washed and incubated on a layer of HBEC-5i grown on a Petri dish. After incubation, the dish is gently washed free from uRBC and unbound iRBC. Fresh uRBC are added to the few iRBC attached to HBEC-5i and incubated overnight. As schizont stage parasites burst, merozoites reinvade RBC and these ring stage parasites are harvested the following day. Parasites are cultured until enough material is obtained (typically 2 to 4 weeks) and a new round of selection can be performed. Depending on the P. falciparum strain, 4 to 7 rounds of selection are needed in order to get a population where most parasites bind to HBEC-5i. The binding phenotype is progressively lost after a few weeks, indicating a switch in variant surface antigen gene expression, thus regular selection on HBEC-5i is required to maintain the phenotype. In summary, we developed a selection assay rendering P. falciparum parasites a more "cerebral malaria adhesive" phenotype. We were able to select 3 out of 4 P. falciparum strains on HBEC-5i. This assay has also successfully been used to select parasites for binding to human dermal and pulmonary endothelial cells. Importantly, this method can be used to select tissue-specific parasite populations in order to identify candidate parasite ligands for binding to brain endothelium. Moreover, this assay can be used to screen for putative anti-sequestration drugs(7).Entities:
Mesh:
Year: 2012 PMID: 22230803 PMCID: PMC3369769 DOI: 10.3791/3122
Source DB: PubMed Journal: J Vis Exp ISSN: 1940-087X Impact factor: 1.355
|
|
|
|
| "DMEM incomplete" | DMEM-F12 Ham | 500ml |
| L-glutamine 200mM | 5ml | |
| Penicillin/streptomycin 100X | 5 ml | |
| NaOH 1M | 1.3 ml (adjust pH to 7.4) | |
| "DMEM complete" | "DMEM incomplete" | 450ml |
| Foetal Bovine Serum heat-inactivated | 50ml | |
| Endothelial cell growth supplement | 5 ml |
|
|
|
|
| "RPMI incomplete" | RPMI 1640 (with bicarbonate) | 500ml |
| Hepes 1M | 12.5ml | |
| Glucose 20% | 5ml | |
| L-glutamine 200mM | 5ml | |
| Gentamycin 50mg/ml | 250μl | |
| NaOH 1M | 0.7 ml (adjust pH to 7.2) | |
| "RPMI complete" | "RPMI incomplete" | 450ml |
| Pooled human (non-immune) serum | 50ml |
|
|
|
|
|
| DMEM-F12 Ham | Sigma | D6421 | For DMEM complete medium |
| L-glutamine 200mM | GIBCO | 25030 | For DMEM and RPMI complete medium |
| Penicillin/streptomycin 100X (10000 units/ml and 10mg/ml) | ScienCell | 0503 | For DMEM complete medium |
| Foetal Bovine Serum heat-inactivated | ScienCell | 0025 | For DMEM complete medium |
| Trypsin-EDTA (0.025% Trypsin, 0.5mM EDTA) | ScienCell | 0103 | |
| Endothelial cell growth supplement | ScienCell | 1052 | For DMEM complete medium |
| Tissue culture treated 60 mm X 15 mm Petri dishes | BD | 353002 | |
| Human Fibronectin | Millipore | FC010 | Use at 2 μg/cm2 |
| TNF | R&D Systems | 210-TA | optional, use at 50 μg/ml |
| RPMI 1640 | Lonza | BE12-167F | For RPMI complete medium |
| Gentamycin 50mg/ml | Lonza | 17-518Z | For RPMI complete medium |
| Hepes 1M | Lonza | BE17-737E | For RPMI complete medium |
| HDMEC | ScienCell | 2000 | Primary cell line |
| HPMEC | ScienCell | 3000 | Primary cell line |
| HBEC-5i | Obtained from Francisco Candal (fcandal@cdc.gov) |